PATIENT Act of 2015

Summary

Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 or the PATIENT Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration. A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to: promote greater patient adherence to an approved treatment regime, reduce the public health risks associated with the drug, reduce side effects or adverse events, provide benefits to the health-care system, or provide other comparable patient benefits.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 13 March 2015

   Introduced

   Referred to the House Committee on Energy and Commerce.

   Source: IntroReferral

2. 13 March 2015

   Introduced

   Introduced in House

   Source: IntroReferral

3. 13 March 2015

   Introduced

   Introduced in House

   Source: IntroReferral

4. 20 March 2015

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 13 March 2015 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 13 March 2015

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 13 March 2015

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 13 March 2015

  Open at official source

Sponsors

• Rep. Bilirakis, Gus M. [R-FL-12] · R · Sponsor
• Gerald Connolly · D · Sponsor
• Rep. Israel, Steve [D-NY-3] · D · Sponsor
• H. Griffith · R · Sponsor
• Susan Brooks · R · Cosponsor
• · hsif00 · Standing

Related records

No cross-record relationships stored yet.